Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials.

ABSTRACT: The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76-0.95, p = 0.004; I ² = 0, p = 0.48).

Supplementary information

The online version contains supplementary material available at 10.1007/s13340-021-00515-4.

SUBMITTER: Barkas F 

PROVIDER: S-EPMC8179959 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature